← Back to headlines
Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
10 Mar, 09:48 — 10 Mar, 09:48
Related Stories
Key fitness measure is strong predictor of longevity after certain age, study finds
just now
Fire guts medical lab at Plateau college
just now
Organ transplantation: 217 registered hospitals fail to report data on National Registry Portal in 2025
11m ago
Health: Innovative solutions for healthcare worker well-being
12m ago